Form 4: Edwards Lifesciences Officer Sells 24,000 Shares

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, reported the sale of 24,000 common shares and a correction in beneficial ownership.

Summary

• Donald E. Bobo Jr., CVP, Strategy/Corp Development at Edwards Lifesciences Corp (EW), sold 24,000 shares of common stock.
• The transaction occurred on February 25, 2026, at a weighted average price of $83.8365 per share.
• Following the sale, Mr. Bobo directly holds 21,266.2532 shares.
• Indirect holdings include 38,900.5862 shares in a 401(k) plan and 121,756 shares held by a trust.
• A correction was made regarding 13,396 shares previously reported as directly held, which are now correctly identified as indirectly held by the Reporting Person's trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to the insider sale, though the correction of beneficial ownership is an administrative detail with no direct market impact.

Negatives

• An officer, Donald E. Bobo Jr., sold 24,000 shares of company common stock, which can be interpreted as a lack of confidence or a move to diversify personal holdings.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

StockSavvy.ai notes that insider selling, while not uncommon for personal financial planning, can sometimes be viewed by the market as a signal regarding management's perception of future company performance or valuation, especially if it's a significant portion of their holdings or part of a broader trend among insiders.

Stakeholder Impact

• Shareholders might interpret the insider sale as a minor negative signal, potentially influencing short-term sentiment.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

While the insider sale by a CVP could be seen as a minor negative signal, it's a single transaction and may be for personal financial planning. Without further context on the company's overall performance or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future insider activity and company news.

Keywords

Edwards Lifesciences, EW, Insider Trading, Stock Sale, Form 4, Beneficial Ownership, Donald E. Bobo Jr., Officer Transaction